Navigation Links
David Blumenthal and Aneesh Chopra Give Keynote Addresses at AMIA's Conference on Anticipating and Addressing Unintended Consequences of HIT and Policy
Date:9/11/2009

BETHESDA, Md., Sept. 11 /PRNewswire-USNewswire/ -- The American Medical Informatics Association (AMIA) released a framework for classifying and assessing unintended consequences of health information technology (HIT) and policy during its 4th Annual invitational Health Policy Conference. The conference, held on September 9 and 10, 2009, in Reston, Virginia, drew diverse stakeholders from the public and private sectors who focused their discussions on anticipating unintended consequences of HIT and policy, as well as options for addressing them. Keynote presentations were made by David Blumenthal, MD, PhD, National HIT Coordinator, and Aneesh Chopra, MPP, Chief Technology Officer and Associate Director for Technology in the White House Office of Science & Technology Policy.

Edward Shortliffe, MD, PhD, AMIA president and CEO, noted that "the healthcare environment is evolving rapidly. With the passage of the American Recovery and Reinvestment Act (ARRA), the United States is investing significantly in HIT in general and electronic health records (EHRs) in particular. They are viewed as a national imperative to improve healthcare delivery and quality and to reduce healthcare costs. AMIA has identified the roles of stakeholders (including government, industry, organizations, and biomedical and health informaticians) in anticipating and addressing unintended consequences."

During his remarks, David Blumenthal called for "the creation of a learning community" within HIT. Justin Starren, MD, PhD, FACMI, co-chair of the meeting and Director, Biomedical Informatics Research Center, Marshfield Clinic, observed, "It goes without saying that any endeavor of this scale will produce unintended and unanticipated consequences. We can learn from those consequences and improve our systems, but only if organizations are encouraged to share their experiences, both good and bad, in implementing t
'/>"/>

SOURCE American Medical Informatics Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Allied Worlds David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium
2. Pro Quarterback David Garrard Aims to Score Big For Crohns Disease During the 2009 Football Season
3. Health Expert Dr. David Friedman Reveals Which Sweeteners Are Best
4. Dr. David Okrongly Appointed CEO of Quanterix Corporation
5. Jackson & Coker Names David Booher Vice President of Emergency Medicine Recruitment
6. Phoenix Cardiovascular Surgeon, David J. Caparrelli, M.D. Becomes Member of the Society for Vascular Surgery
7. Re-Envision Your Look: Dr. David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures
8. Huntsville, Alabama Plastic Surgeon David L. Durst, MD Comments on Silicone Breast Implants after Nearly 3 Years on the Open Market
9. Dr. David Williams Featured on Searchvitaminsupplements.com
10. Cornerstone Therapeutics David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal
11. Coming Clean About The Cleaner - Phoenix Houses Chief Clinical Officer David Deitch on Intervention, and the Recovery Process That Follows
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Survivors of childhood cancer less likely to marry 10291 1Survivors of childhood cancer less likely to marry 10291 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 1HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 3Statewide Drug Card Program Launching 59108 1